Summit Partners Public Asset Management LLC Decreases Stake in RxSight, Inc. (NASDAQ:RXST)

Summit Partners Public Asset Management LLC reduced its position in RxSight, Inc. (NASDAQ:RXST) by 15.5% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 687,711 shares of the company’s stock after selling 126,122 shares during the period. RxSight accounts for approximately 1.1% of Summit Partners Public Asset Management LLC’s portfolio, making the stock its 21st largest holding. Summit Partners Public Asset Management LLC owned approximately 1.71% of RxSight worth $33,994,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Amalgamated Bank raised its position in shares of RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after purchasing an additional 207 shares during the period. Principal Financial Group Inc. raised its holdings in RxSight by 0.7% during the 3rd quarter. Principal Financial Group Inc. now owns 36,046 shares of the company’s stock valued at $1,782,000 after acquiring an additional 240 shares during the period. Crossmark Global Holdings Inc. lifted its position in shares of RxSight by 3.2% during the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock worth $473,000 after acquiring an additional 242 shares in the last quarter. RiverPark Advisors LLC boosted its holdings in shares of RxSight by 9.6% in the second quarter. RiverPark Advisors LLC now owns 3,379 shares of the company’s stock worth $203,000 after acquiring an additional 297 shares during the period. Finally, CWM LLC grew its position in shares of RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares in the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

RxSight Trading Up 0.7 %

Shares of NASDAQ:RXST opened at $46.40 on Friday. RxSight, Inc. has a 52-week low of $28.88 and a 52-week high of $66.54. The firm has a fifty day moving average of $48.85 and a 200 day moving average of $52.44.

Analysts Set New Price Targets

A number of analysts recently issued reports on RXST shares. Needham & Company LLC reissued a “buy” rating and set a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Jefferies Financial Group initiated coverage on shares of RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective for the company. Oppenheimer lowered their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus reduced their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Finally, Wells Fargo & Company lowered their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $61.63.

Insider Transactions at RxSight

In related news, insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $52.67, for a total value of $163,277.00. Following the completion of the sale, the insider now owns 42,246 shares in the company, valued at $2,225,096.82. The trade was a 6.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Shweta Maniar sold 3,782 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16. Following the transaction, the director now owns 10,902 shares in the company, valued at $500,183.76. The trade was a 25.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 62,702 shares of company stock worth $3,059,197. 9.36% of the stock is currently owned by corporate insiders.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.